Literature DB >> 15071039

Evaluation of the Velogene genomic assay for detection of vanA and vanB genes in vancomycin-resistant Enterococcus species.

Maria D Appleman1, Diane M Citron, Richard Kwok.   

Abstract

The Velogene (VEL) genomic assay is a qualitative DNA probe for vanA and vanB in enterococci. 150 clinical isolates were tested with the VEL assay and characterized by pigment production, catalase levels, motility, growth in 6 micro g of vancomycin/ml, vancomycin and teicoplanin susceptibility, API 20S assay, and genotyping by multiplex PCR. The VEL assay identified all enterococcal strains with vanA and vanB genes.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15071039      PMCID： PMC387590          DOI： 10.1128/JCM.42.4.1751-1752.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  6 in total

Review 1.  Insights into the epidemiology and control of infection with vancomycin-resistant enterococci.

Authors:  M K Hayden
Journal:  Clin Infect Dis       Date:  2000-10-25       Impact factor: 9.079

Review 2.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

3.  Cycling probe technology with RNase H attached to an oligonucleotide.

Authors:  F Bekkaoui; I Poisson; W Crosby; L Cloney; P Duck
Journal:  Biotechniques       Date:  1996-02       Impact factor: 1.993

4.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.

Authors:  R Leclercq; E Derlot; J Duval; P Courvalin
Journal:  N Engl J Med       Date:  1988-07-21       Impact factor: 91.245

5.  Detection of vancomycin resistant genes vanA and vanB by cycling probe technology.

Authors:  Z Modrusan; C Marlowe; D Wheeler; M Pirseyedi; R N Bryan
Journal:  Mol Cell Probes       Date:  1999-06       Impact factor: 2.365

Review 6.  Emergence of vancomycin-resistant enterococci.

Authors:  L B Rice
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.